Semaglutide and tirzepatide potential to transform type 1 diabetes treatment

A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and tirzepatide leads to significant reductions in HbA1c levels and body weight among adults with type 1 diabetes (T1D).

These findings suggest a potential new therapeutic approach for improving glycemic control and addressing obesity in T1D, an area with few pharmacologic advancements beyond insulin therapy, according to pharma analytics company GlobalData.

Semaglutide is the active ingredient of Novo Nordisk’s (NOV: N) diabetes drug Ozempic and weight management brand Wegovy, whereas tirzepatide is likewise for Eli Lily’s (NYSE: LLY) for diabetes drug Mounjaro and obesity brand Zepbound, all of which have generated billions of dollars sales for the companies and contributed to massive capitalization gains.